16:55 , Apr 19, 2019 |  BC Week In Review  |  Company News

BioSense gets Asia rights to Rexahn's pancreatic cancer therapy

BioSense gained exclusive rights to develop and commercialize Rexahn's RX-3117 to treat and prevent pancreatic cancer in Singapore, China, Hong Kong, Macau and Taiwan. Rexahn Pharmaceuticals Inc. (NYSE-A:RNN) will receive $3 million up front and...
20:47 , Oct 5, 2018 |  BC Week In Review  |  Company News

BioSense exercises option for Chinese rights to Neovacs's IFNalpha Kinoid to treat lupus

BioSense Global LLC (East Rutherford, N.J.) exercised its option under a 2017 deal to acquire exclusive rights from Neovacs S.A. (Euronext:ALNEV) to develop and commercialize IFNalpha-Kinoid to treat lupus, in China. Neovacs will receive an...